Skip to main content

Eucrisa FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved December 14, 2016)
Brand name: Eucrisa
Generic name: crisaborole
Dosage form: Topical Ointment
Company: Pfizer Inc.
Treatment for: Atopic Dermatitis

Eucrisa (crisaborole) is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Development timeline for Eucrisa

DateArticle
Mar 24, 2020Approval FDA Approves Eucrisa (crisaborole) Ointment 2% in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
Dec 14, 2016Approval FDA Approves Eucrisa (crisaborole) for Eczema
Mar 22, 2016Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
Jan  7, 2016Anacor Pharmaceuticals Submits NDA to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis

See also

Eucrisa (crisaborole) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer